Agenus Inc (AGEN)

$4.34 +0.01 (0.23%)
Market Cap 147.60M
Revenue (ttm) 103.46M
Net Income (ttm) -227.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 2.65
Profit Margin -219.61%
Debt to Equity Ratio -0.10
Volume 366,400
Avg Vol 487,468
Day's Range N/A - N/A
Shares Out 34.01M
Stochastic %K 67%
Beta 1.43
Analysts Sell
Price Target $12.33

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 674 4400
Fax: 781 674 4200
Address:
3 Forbes Road, Lexington, United States
Moon37
Moon37 Nov. 17 at 12:43 PM
$AGEN (estimated) in Garo speak means at least a year or something
0 · Reply
joechuck71
joechuck71 Nov. 17 at 1:43 AM
$AGEN Study Start 2025-11-30 [Estimated]
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 10:41 PM
Hedge Alert Live - Protect Your Portfolio Contract: $AGEN $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.31 - $0.65 Exit Price Target: $0.74 Profit Margin: +138% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
neversurrender2024
neversurrender2024 Nov. 16 at 2:24 PM
$AGEN be aware of garo and his groupies playing on your empathy to invest here!
1 · Reply
BakerBrother
BakerBrother Nov. 16 at 1:44 PM
$AGEN Tik Tok is full of heart wrenching MSS-CRC patients, most of whom don’t bother with YouTube because the YouTube platform makes it harder to reach an audience. Marketing 101.
2 · Reply
BakerBrother
BakerBrother Nov. 16 at 3:15 AM
$AGEN this is so heartbreaking: https://www.tiktok.com/t/ZP8DvT48V/
2 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 12:24 AM
💎 LiquidTheta® Live Actionable Trade Asset: $AGEN Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.63- $1.99 Scale out: $6.34-$10.88 Profit Potential : 87% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:44 PM
Hedge Alert Live - Protect Your Portfolio Contract: $AGEN $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.31 - $0.65 Exit Price Target: $0.74 Profit Margin: +138% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Wendy_Veg
Wendy_Veg Nov. 15 at 4:31 PM
$AGEN Agenus held through a volatile week fairly well. With the government shutdown, what can we expect from the CFIUS review of the ful notice application of the Zydus deal? Any speculation of the steady, upward price signal recently?
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 12:00 AM
💎 LiquidTheta® Live Actionable Trade Asset: $AGEN Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.53- $1.87 Scale out: $5.95-$10.20 Profit Potential : 260% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
Latest News on AGEN
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Nov 10, 2025, 7:30 AM EST - 7 days ago

Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Nov 5, 2025, 1:47 PM EST - 11 days ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Oct 21, 2025, 8:44 PM EDT - 26 days ago

Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Oct 17, 2025, 8:00 AM EDT - 4 weeks ago

Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

Oct 16, 2025, 7:48 AM EDT - 4 weeks ago

Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Sep 9, 2025, 7:43 AM EDT - 2 months ago

France Grants Reimbursed Compassionate Access (AAC) for Agenus' BOT/BAL in Refractory MSS Metastatic Colorectal Cancer

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 8:52 AM EDT - 2 months ago

Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Aug 28, 2025, 2:04 PM EDT - 2 months ago

Agenus Inc. (AGEN) Virtual Stakeholder Briefing Call (Transcript)

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Aug 26, 2025, 9:37 AM EDT - 2 months ago

Update: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Aug 19, 2025, 7:30 AM EDT - 3 months ago

Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Aug 11, 2025, 7:30 AM EDT - 3 months ago

Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Jul 25, 2025, 12:46 PM EDT - 4 months ago

Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jul 7, 2025, 8:55 AM EDT - 4 months ago

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 17, 2025, 7:30 AM EDT - 5 months ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Agenus Announces Virtual Annual Shareholders Meeting

Jun 10, 2025, 1:30 PM EDT - 5 months ago

Agenus Announces Virtual Annual Shareholders Meeting

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 4, 2025, 2:38 PM EDT - 5 months ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Jun 3, 2025, 7:00 AM EDT - 5 months ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 30, 2025, 7:30 AM EDT - 6 months ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 23, 2025, 3:09 PM EDT - 6 months ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 15, 2025, 10:40 AM EDT - 6 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 2:46 PM EDT - 6 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:30 AM EDT - 6 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

May 12, 2025, 7:20 AM EDT - 6 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 29, 2025, 7:30 AM EDT - 7 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 28, 2025, 3:30 PM EDT - 7 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 25, 2025, 1:05 PM EDT - 7 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Apr 23, 2025, 12:05 PM EDT - 7 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 25, 2025, 4:40 PM EDT - 8 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 19, 2025, 7:30 AM EDT - 8 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 10:39 AM EDT - 8 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Mar 11, 2025, 7:30 AM EDT - 8 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 26, 2025, 4:48 PM EST - 9 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 2:30 PM EST - 9 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 25, 2025, 8:26 AM EST - 9 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 24, 2025, 8:33 AM EST - 9 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 9 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 9 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 29, 2025, 12:37 PM EST - 10 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Jan 22, 2025, 2:48 PM EST - 10 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 18, 2024, 7:30 AM EST - 11 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Dec 5, 2024, 7:30 AM EST - 1 year ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 27, 2024, 8:15 AM EST - 1 year ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 10:41 AM EST - 1 year ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 12, 2024, 7:00 AM EST - 1 year ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 7, 2024, 10:00 AM EST - 1 year ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 5, 2024, 7:30 AM EST - 1 year ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 1 year ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Moon37
Moon37 Nov. 17 at 12:43 PM
$AGEN (estimated) in Garo speak means at least a year or something
0 · Reply
joechuck71
joechuck71 Nov. 17 at 1:43 AM
$AGEN Study Start 2025-11-30 [Estimated]
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 16 at 10:41 PM
Hedge Alert Live - Protect Your Portfolio Contract: $AGEN $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.31 - $0.65 Exit Price Target: $0.74 Profit Margin: +138% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
neversurrender2024
neversurrender2024 Nov. 16 at 2:24 PM
$AGEN be aware of garo and his groupies playing on your empathy to invest here!
1 · Reply
BakerBrother
BakerBrother Nov. 16 at 1:44 PM
$AGEN Tik Tok is full of heart wrenching MSS-CRC patients, most of whom don’t bother with YouTube because the YouTube platform makes it harder to reach an audience. Marketing 101.
2 · Reply
BakerBrother
BakerBrother Nov. 16 at 3:15 AM
$AGEN this is so heartbreaking: https://www.tiktok.com/t/ZP8DvT48V/
2 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 16 at 12:24 AM
💎 LiquidTheta® Live Actionable Trade Asset: $AGEN Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.63- $1.99 Scale out: $6.34-$10.88 Profit Potential : 87% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 15 at 10:44 PM
Hedge Alert Live - Protect Your Portfolio Contract: $AGEN $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.31 - $0.65 Exit Price Target: $0.74 Profit Margin: +138% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Wendy_Veg
Wendy_Veg Nov. 15 at 4:31 PM
$AGEN Agenus held through a volatile week fairly well. With the government shutdown, what can we expect from the CFIUS review of the ful notice application of the Zydus deal? Any speculation of the steady, upward price signal recently?
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 15 at 12:00 AM
💎 LiquidTheta® Live Actionable Trade Asset: $AGEN Contracts: $AGEN January 15, 2027 $5 Calls Scale in: $1.53- $1.87 Scale out: $5.95-$10.20 Profit Potential : 260% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
TcXG2KWy
TcXG2KWy Nov. 14 at 10:31 PM
$AGEN I'm filling it with positive thoughts.
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 6:27 PM
Hedge Alert Live - Protect Your Portfolio Contract: $AGEN $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.31 - $0.75 Exit Price Target: $0.72 Profit Margin: +131% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
UltimoDaBaggie
UltimoDaBaggie Nov. 14 at 3:08 PM
$AGEN Seems every morning Garo ATMs.
1 · Reply
BakerBrother
BakerBrother Nov. 14 at 2:55 PM
$AGEN does anyone know how to measure something called “money flow”?
1 · Reply
GDS_investing
GDS_investing Nov. 14 at 2:23 PM
$CDTX great $VTVT or $AGEN is next all for long
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:47 AM
Hedge Alert Live - Protect Your Portfolio Contract: $AGEN $4.00 Put · NOV 21, 2025 Exp Entry Price: $0.31 - $0.75 Exit Price Target: $0.45 Profit Margin: +46% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Biotechguy21
Biotechguy21 Nov. 13 at 11:32 PM
$AGEN ut oh look out! Look who is back. 🤡🤡😂😂
0 · Reply
Scooter0732
Scooter0732 Nov. 13 at 8:33 PM
$AGEN Held up strong today considering the selloff.
2 · Reply
BakerBrother
BakerBrother Nov. 13 at 8:10 PM
$AGEN Bot/Bal - coming to a country near you!
2 · Reply
UltimoDaBaggie
UltimoDaBaggie Nov. 13 at 5:38 PM
$AGEN Despite all this dilution, SP remains steady. Someone must have been and must be accumulating. Last year, I was but I ran out of funds. I hope Garo gets his act together. We dont have decades to bring bot/bal to patients
1 · Reply
Biotechguy21
Biotechguy21 Nov. 13 at 2:50 PM
$AGEN it is going somewhere and that is down to zero 🤡🤡😂😂👇👇💩💩💩
0 · Reply
neversurrender2024
neversurrender2024 Nov. 13 at 2:36 PM
$AGEN 32,814,429 outstanding shares as of sept 30th 34,008,349 as of nov7 th 1193920 shares diluted in a little over a month this company is going no where!
0 · Reply